Trial Profile
Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Riluzole (Primary)
- Indications Social phobia
- Focus Proof of concept; Therapeutic Use
- 22 Feb 2021 Status changed from active, no longer recruiting to completed.
- 14 Nov 2018 According to a Biohaven Pharmaceutical Holding Company media release, the FDA (in Nov 2018) has agreed to a modification of the trials primary endpoint, the Scale for Assessment and Rating of Ataxia (SARA) as an acceptable registrational endpoint.
- 16 Aug 2018 According to Biohaven Pharmaceuticals media release, the company expects to present additional results from this trial at upcoming scientific meetings over the next year. Based upon these trial results, Biohaven plans to expand its glutamate modulating platform development program to include the treatment of Generalized anxiety disorder (GAD).